PharmaCyte Biotech Inc (PMCB)


Stock Price Forecast

Feb. 21, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading PharmaCyte Biotech Inc chart...

About the Company

PharmaCyte Biotech, Inc. is a biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as "Cell-in-a-Box®." This technology is being used as a platform upon which therapies for several types of cancer and diabetes are being developed. PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or "cancer-killing" form.

Employees

4

Exchange

NASDAQ

Website

www.pharmacytebiotech.com

$0M

Total Revenue

4

Employees

$23M

Market Capitalization

-2.55

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $PMCB News

PMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q3 2024

on MSN ago, source:

PharmaCyte Biotech (NASDAQ:PMCB) just reported results for the third quarter of 2024. PharmaCyte Biotech reported earnings ...

PharmaCyte Biotech (PMCB) Earnings Dates & Reports

1mon ago, source: Investing

View upcoming earnings forecasts and in-depth analysis of company forecasts.

Wayne Remell Walker's Net Worth

22d ago, source: Benzinga.com

PharmaCyte Biotech, Inc. (PMCB) Snapshot price: $2.3 ...

PharmaCyte Biotech Inc PMCB

21d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

PharmaCyte Biotech, Inc. Common Stock (PMCB)

5mon ago, source: Nasdaq

Nasdaq provides press releases highlighting valuable information sent out by companies. Here you can find the company’s latest financial figures, contact information, and source version of the ...

PharmaCyte Biotech Inc.

3y ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

PharmaCyte Biotech, Inc. Common Stock (PMCB)

6y ago, source: Nasdaq

*The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. It is possible that this date will be updated in the future, once the company announces ...

PharmaCyte Biotech Inc (PMCB)

28d ago, source: Investing

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

PharmaCyte Biotech, Inc. (PMCB)

8mon ago, source: Yahoo Finance

LAS VEGAS, November 15, 2023--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) ("PharmaCyte" or the "Company") announces it has made a $5 million investment in Femasys, Inc. (Nasdaq:FEMY) ("Femasys"), a ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...